References
- Astakhova AV, Lepakhin VK. Adverse Reactions and Safety Monitoring, 2nd edn. Moscow: EKSMO Publishing, 2008
- Khoseva EN, Norozova TE. Problematic aspects of pharmacovigilance systems in the Russian Federation at the present stage (review). Good Clinical Practice 2013;3:3-7
- Lenz W, Knapp K. Thalidomide embryopathy. Dtsch Med Wochenschr 1962;15:1232-42
- Mcbride WG. Thalidomide and congenital abnormalities. Lancet 1961;278:1358
- Babayan EA. Some aspects of the adverse drug reaction. Side Effects of Drugs 1976;6:7-10
- Astakhova AV, Lepakhin VK. Adverse reactions and drug’s safety monitoring: guidelines for pharmacovigilance. Moscow: Kogito-center, 2004:200
- Ovchinnikova EA. Role of drug’s safety monitoring in resolving the issue of drugs rational use. Good Clinical Practice 2003;4:88-95
- The Federal Law of the Russian Federation №86-FZ, enacted on 22 June 1998, On Medicines
- Kolbin AS, Zagorodnikova KA, Burbello AT. PV in the Russian Federation and in the European Union in the light of new EU directives. Are there any changes, waiting for us? Moscow/Remedium, 2012
- The Federal Law of the Russian Federation №61-FZ, enacted on 12 April 2010 “On circulation of drugs”, articles 64–66 of chapter 13
- Order №757n of the Ministry of Health of Russia, dated 26 August 2010 “On approval of the procedure of monitoring of medicines safety, registration of adverse reactions, serious adverse reactions, unexpected adverse reactions in the use of medicines”
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Association of International Pharmaceutical Manufacturers (AIPM). “Good Pharmacovigilance Principles and Considerations for Biotherapeutic Medicines”, Moscow: AIPM, 2016
- Tandon VR, Mahajan V, Khajuria V, Gillani Z. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India”. Indian J Pharmacol 2015;47:65-71
- Biagi C, Montanaro N, Buccellato E, et al. Underreporting in PV: an intervention for Italian GPs (Emilia-Romagna region). Eur J Clin Pharmacol 2013;69:237-44
- Inman WH. Attitudes to adverse drug reaction reporting. Br J Clin Pharmacol 1996;41:434
- Khoseva EN, Morozova TE, Ermakov DA, Oshorova SD. Issues on control of medication safety in clinical practice: position of patients and medical staff. The Doctor–Postgraduate 2013;2:203-12
- Van Grootheest K, de Jong van den Berg L. Patients’ role in reporting adverse drug reactions. Expert Opin Drug Saf 2004;3:363-8
- Foster JM, van der Molen T, de Jong van den Berg L. Patient reporting of side effects may provide an important source of information in clinical practice. Eur J Clin Pharmacol 2007;63:979-80
- Khoseva EN, Morozova TE, Andrushishina TB. Safety and efficacy of today’s remedies from patients’ viewpoint. Clin Pharmacol Ther 2012;21:30-4
- Edwards IR, Lindquist M. Understanding and communicating key concepts in risk management: what do we mean by benefit and risk? Drug Saf 2009;32:449-52
- Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010. Official Journal of the European Union 2010;348:1-16
- Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010. Official Journal of the European Union 2010;348:74-99
- Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Saf 2004;27:569-78
- Order №66 of the Ministry of Health of Russia, dated 13 February 2013 (ed. dated 7 April 2016). On approval of the strategy of drug provision of the population of the Russian Federation for the period up to 2025 and its implementation plan